188 related articles for article (PubMed ID: 32682445)
1. Platelet count as a biomarker for monitoring treatment response and disease recurrence in recurrent epithelial ovarian cancer.
Hu Q; Hada A; Han L
J Ovarian Res; 2020 Jul; 13(1):78. PubMed ID: 32682445
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment plasma D-dimer, fibrinogen, and platelet levels significantly impact prognosis in patients with epithelial ovarian cancer independently of venous thromboembolism.
Man YN; Wang YN; Hao J; Liu X; Liu C; Zhu C; Wu XZ
Int J Gynecol Cancer; 2015 Jan; 25(1):24-32. PubMed ID: 25347092
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of pretreatment thrombocytosis in epithelial ovarian cancer.
Okunade KS; Dawodu O; Adenekan M; Nwogu CM; Awofeso O; Ugwu AO; Salako O; John-Olabode S; Olowoselu OF; Anorlu RI
Niger J Clin Pract; 2020 Aug; 23(8):1141-1147. PubMed ID: 32788493
[TBL] [Abstract][Full Text] [Related]
4. Differential platelet levels affect response to taxane-based therapy in ovarian cancer.
Bottsford-Miller J; Choi HJ; Dalton HJ; Stone RL; Cho MS; Haemmerle M; Nick AM; Pradeep S; Zand B; Previs RA; Pecot CV; Crane EK; Hu W; Lutgendorf SK; Afshar-Kharghan V; Sood AK
Clin Cancer Res; 2015 Feb; 21(3):602-10. PubMed ID: 25473001
[TBL] [Abstract][Full Text] [Related]
5. Preoperative plasma fibrinogen, platelet count and prognosis in epithelial ovarian cancer.
Qiu J; Yu Y; Fu Y; Ye F; Xie X; Lu W
J Obstet Gynaecol Res; 2012 Apr; 38(4):651-7. PubMed ID: 22413879
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of thrombocytosis, platelet parameters and aggregation rates in epithelial ovarian cancer.
Ma X; Wang Y; Sheng H; Tian W; Qi Z; Teng F; Xue F
J Obstet Gynaecol Res; 2014 Jan; 40(1):178-83. PubMed ID: 24102732
[TBL] [Abstract][Full Text] [Related]
7. Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer.
Chen JP; Huang QD; Wan T; Tu H; Gu HF; Cao JY; Liu JH
J Ovarian Res; 2019 Jul; 12(1):72. PubMed ID: 31362750
[TBL] [Abstract][Full Text] [Related]
8. Thrombocytosis at secondary cytoreduction for recurrent ovarian cancer predicts suboptimal resection and poor survival.
Cohen JG; Tran AQ; Rimel BJ; Cass I; Walsh CS; Karlan BY; Li AJ
Gynecol Oncol; 2014 Mar; 132(3):556-9. PubMed ID: 24423879
[TBL] [Abstract][Full Text] [Related]
9. Elevated plasma fibrinogen levels and prognosis of epithelial ovarian cancer: a cohort study and meta-analysis.
Luo Y; Kim HS; Kim M; Lee M; Song YS
J Gynecol Oncol; 2017 May; 28(3):e36. PubMed ID: 28382799
[TBL] [Abstract][Full Text] [Related]
10. The prediction of progression-free and overall survival in women with an advanced stage of epithelial ovarian carcinoma.
Gerestein CG; Eijkemans MJ; de Jong D; van der Burg ME; Dykgraaf RH; Kooi GS; Baalbergen A; Burger CW; Ansink AC
BJOG; 2009 Feb; 116(3):372-80. PubMed ID: 19187369
[TBL] [Abstract][Full Text] [Related]
11. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J
Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821
[TBL] [Abstract][Full Text] [Related]
12. [The relationship of preoperativelymphocyte-monocyte ratio and the clinicopathological characteristics and prognosis of patients with epithelial ovarian cancer].
Yang HM; Lou G
Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):676-680. PubMed ID: 28926896
[No Abstract] [Full Text] [Related]
13. Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer.
Chambers LM; Kuznicki M; Yao M; Chichura A; Gruner M; Reizes O; Debernardo R; Rose PG; Michener C; Vargas R
Gynecol Oncol; 2020 Dec; 159(3):699-705. PubMed ID: 32950250
[TBL] [Abstract][Full Text] [Related]
14. Role of protein tyrosine phosphatase receptor type M in epithelial ovarian cancer progression.
Li X; Ding W; Rao Y; Qu P
J Ovarian Res; 2023 Jul; 16(1):131. PubMed ID: 37403117
[TBL] [Abstract][Full Text] [Related]
15. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy.
Miao Y; Yan Q; Li S; Li B; Feng Y
Cancer Biomark; 2016 Jun; 17(1):33-40. PubMed ID: 27314290
[TBL] [Abstract][Full Text] [Related]
16. Preoperative plasma D-dimer level is a useful prognostic marker in ovarian cancer.
Yamada Y; Kawaguchi R; Iwai K; Niiro E; Morioka S; Tanase Y; Kobayashi H
J Obstet Gynaecol; 2020 Jan; 40(1):102-106. PubMed ID: 31335252
[TBL] [Abstract][Full Text] [Related]
17. Platelet Count After Chemotherapy is a Predictor for Outcome for Ovarian Cancer Patients.
Eggemann H; Ehricke J; Ignatov T; Fettke F; Semczuk A; Costa SD; Ignatov A
Cancer Invest; 2015 May; 33(5):193-6. PubMed ID: 25831456
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the prognostic significance of preoperative thrombocytosis in epithelial ovarian cancer.
Allensworth SK; Langstraat CL; Martin JR; Lemens MA; McGree ME; Weaver AL; Dowdy SC; Podratz KC; Bakkum-Gamez JN
Gynecol Oncol; 2013 Sep; 130(3):499-504. PubMed ID: 23747328
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of protein kinase CK2α correlates with poor patient prognosis in epithelial ovarian cancer.
Ma Z; Wang X; He J; Xia J; Li Y
PLoS One; 2017; 12(3):e0174037. PubMed ID: 28355289
[TBL] [Abstract][Full Text] [Related]
20. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
Skaznik-Wikiel ME; Lesnock JL; McBee WC; Beriwal S; Zorn KK; Richard SD; Krivak TC; Edwards RP
Int J Gynecol Cancer; 2012 Feb; 22(2):232-7. PubMed ID: 22080886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
